Pleiotropic Benefits of Statins in Cardiovascular Diseases

Abstract

In 1976, Japanese microbiologist Akira Endo discovered the first statin as a product of the fungus Penicillium citrinum that inhibited the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Their primary mode of action is to lower the blood cholesterol by decreasing hepatic cholesterol production, which upregulates hepatic low-density lipoprotein (LDL) receptors and increases LDL-cholesterol clearance. In addition to cholesterol lowering, statins inhibit other downstream products of the mevalonate pathway, causing the so-called pleiotropic effects. As a result of their pleiotropic effects statins modulate virtually all known processes of atherosclerosis and have beneficial effects outside the cardiovascular system Statins inhibit the post-translational prenylation of small GTP-binding proteins such as Rho, Rac, as well as their downstream effectors such as Rho kinase and nicotinamide adenine dinucleotide phosphate oxidases since they suppress the synthesis of isoprenoid intermediates in the cholesterol biosynthetic pathway altering the expression of endothelial nitric oxide synthase, the stability of atherosclerotic plaques, production of proinflammatory cytokines, reactive oxygen species, platelet reactivity, development of cardiac hypertrophy and fibrosis in cell culture and animal experiments. Inhibition of Rho and Rho-associated coiled-coil containing protein kinase (ROCK), has emerged as the principle mechanisms underlying the pleiotropic effects of statins. However, the relative contributions of statin pleiotropy to clinical outcomes are debatable and difficult to measure because the amount of isoprenoid inhibition by statins corresponds to some extent with the amount of LDL-cholesterol decrease. This article examines some of the existing molecular explanations underlying statin pleiotropy and discusses if they have clinical relevance in cardiovascular diseases.

Key words

Cardiovascular diseases - Statins - Pleiotropic effect

Publication History

Received: 16 May 2022

Accepted: 07 June 2022

Article published online:
22 July 2022

• References

• 1 Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 484-493
• 2 Alberts AW, Chen J, Kuron G. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A I. 1980; 77: 3957-3961
• 3 Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thrombos Vasc Biol 2000; 20: 556-562 DOI: 10.1161/01.ATV.20.2.556.
• 4 Lefer AM, Campbell B, Shin Y-K. et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circ 1990; 100: 178-184 DOI: 10.1161/01.CIR.100.2.178.
• 5 Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thrombos Vasc Biol 1999; 19: 2894-2900 DOI: 10.1161/01.atv.19.12.2894.
• 6 Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514 DOI: 10.1126/science.279.5350.509.
• 7 Node K, Fujita M, Kitakaze M. et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circ 2003; 108: 839-843 DOI: 10.1161/01.CIR.0000115211.60667.A6.
• 8 Sirtori CR. The pharmacology of statins. Pharmacol Res 2014; 88: 3-11 DOI: 10.1016/j.phrs.2014.03.002..
• 9 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125 DOI: 10.1111/j.1472-8206.2004.00299.x..
• 10 Sakamoto K, Mikami H, Kimura J. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. Br J Pharmacol 2008; 154: 1482-1490 DOI: 10.1038/bjp.2008.192..
• 11 Weitz-Schmidt G, Welzenbach K, Brinkmann V. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692 DOI: 10.1038/89058..
• 12 Blanco-Colio LM, Martín-Ventura JL, de Teresa E. et al. ACTFAST investigators. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007; 153: 881-888 DOI: 10.1016/j.ahj.2007.02.029.
• 13 Available from: https://www.framinghamheartstudy.org/about-fhs/history.php [Accessed 25 April 2022]
• 14 Cho KJ, Hill MM, Chigurupati S. et al. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol 2011; 31: 1110-1120 DOI: 10.1128/MCB.00989-10.
• 15 Laufs U, La V, Plutzky J. et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circ 1998; 97: 1129-1135 DOI: 10.1161/01.CIR.97.12.1129.
• 16 Awan Z, Seidah NG, MacFadyen JG. et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012; 58: 183-189 DOI: 10.1373/clinchem.2011.172932.
• 17 Griendling KK, Minieri CA, Ollerenshaw JD. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
• 18 Zafari AM, Ushio-Fukai M, Akers M. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-495 DOI: 10.1161/01.hyp.32.3.488.
• 19 Patterson C, Ruef J, Madamanchi NR. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999; 274: 19814-19822 DOI: 10.1074/jbc.274.28.19814.
• 20 Bendall J, Cave A, Heymes C. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II induced cardiac hypertrophy in mice. Circ 2002; 105: 293-296
• 21 Shimizu T, Liao JK. Rho kinases and cardiac remodeling. Circ J 2016; 80: 1491-1498 DOI: 10.1253/circj.CJ-16-0433.
• 22 Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290: C661-C668 DOI: 10.1152/ajpcell.00459.2005.
• 23 Li Q, Xu Y, Li X. Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-β1-TAK1. Toxicol Lett 2012; 211: 91-97 DOI: 10.1016/j.toxlet.2012.03.006.
• 24 Ridker PM, Everett BM, Thuren T. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377: 1119-1131 DOI: 10.1056/NEJMoa1707914.
• 25 Pena JM, MacFadyen J, Glynn RJ. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Euro Heart J 2012; 33: 531-537 DOI: 10.1093/eurheartj/ehr460.
• 26 McNeish AJ, Jimenez-Altayo F, Cottrell GS. et al. Statins and selective inhibition of Rho kinase protect small conductance calciumactivated potassium channel function (K(Ca)2.3) in cerebral arteries. PLoS One 2012; 7: e46735 DOI: 10.1371/journal.pone.0046735.
• 27 Li M, Liu Y, Dutt P. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 293: L463-L471 DOI: 10.1152/ajplung.00133.2007.
• 28 Ma MM, Li SY, Wang M. Simvastatin attenuated cerebrovascular cell proliferation in the development of hypertension through Rho/Rho-kinase pathway. J Cardiovasc Pharmacol 2012; 59: 576-582 DOI: 10.1097/FJC.0b013e318250ba2c.
• 29 Gojo A, Utsunomiya K, Taniguchi K. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568: 242-247 DOI: 10.1016/j.ejphar.2007.04.011.
• 30 Yamanouchi D, Banno H, Nakayama M. et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. Journal of Vascular Surgery 2005; 42: 757-764 DOI: 10.1016/j.jvs.2005.05.0.
• 31 Trebicka J, Hennenberg M, Laleman W. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-253 DOI: 10.1002/hep.21673.
• 32 Rawlings R, Nohria A, Liu PY. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2009; 103: 437-441 DOI: 10.1016/j. amjcard.2008.10.008.
• 33 Liu PY, Liu YW, Lin LJ. et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circ 2009; 119: 131-138 DOI: 10.1161/CIRCULATIONAHA.108.813311.
• 34 Sawada N, Li Y, Liao JK. Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmaco 2010; 10: 116-121 DOI: 10.1016/j.coph.2009.11.004.
• 35 Miller YI, Choi SH, Fang L. et al. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem 2010; 51: 229-251 DOI: 10.1007/978-90-481-8622-8_8.
• 36 Antoniades C, Bakogiannis C, Leeson P. et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circ 2011; 124: 335-345 DOI: 10.1161/CIRCULATIONAHA.110.985150.
• 37 Yano M, Matsumura T, Senokuchi T. et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase ½ and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007; 100: 1442-1451 DOI: 10.1161/01.RES.0000268411.49545.9c.
• 38 Pucci A, Formato L, Muscio M. PPARγ in coronary atherosclerosis: in vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis 2011; 218: 479-485
• 39 Corti R, Osende JI, Fallon JT. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004; 43: 464-473 DOI: 10.1016/j.jacc.2003.08.048.
• 40 Chen M, Li H, Wang G. et al. Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ). Metabolism 2016; 65: 441-453 DOI: 10.1016/j.metabol.2015.11.007.
• 41 Bouitbir J, Charles AL, Echaniz-Laguna A. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J 2012; 33: 1397-1407 DOI: 10.1093/eurheartj/ehr224..
• 42 Preiss D, Seshasai SR, Welsh P. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA 2011; 305: 2556-2564 DOI: 10.1001/jama.2011.860.
• 43 Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271 DOI: 10.1074/jbc.273.37.24266.
• 44 Van-der HM, Versteilen AM, Sipkema P. et al. Rho-kinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusion-induced endothelial cell apoptosis. Apoptosis 2008; 13: 404-412 DOI: 10.1007/s10495-007-0173-6.
• 45 Sen-Banerjee S, Mir S, Lin Z. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circ 2005; 112: 720-726 DOI: 10.1161/CIRCULATIONAHA.104.525774.
• 46 Bu DX, Tarrio M, Grabie N. Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Investig 2010; 120: 1961-1970 DOI: 10.1172/JCI41384.
• 47 Koutouzis M, Nomikos A, Nikolidakis S. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 2007; 192: 457-463 DOI: 10.1016/j. atherosclerosis.2007.01.035.
• 48 Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circ 1998; 98: 82-89 DOI: 10.1161/01.cir.98.1.82.
• 49 Chen Z, Fukutomi T, Zago AC. et al. Simvastatin reduces neointimal thickening in lowdensity lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circ 2002; 106: 20-22 DOI: 10.1161/01.cir.0000022843.76104.01.
• 50 Takemoto M. Statins as Antioxidant Therapy for Preventing Cardiac Myocyte Hypertrophy. J Clin Investig 2001; 108: 1429-1437
• 51 Satoh M, Ogita H, Takeshita K. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U.S.A 2006; 103: 7432-7437 DOI: 10.1073/pnas.0510444103.
• 52 Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nature Reviews Nephrology 2013; 9: 86-98 DOI: 10.1038/nrneph.2012.282..
• 53 Tanaka S, Fukumoto Y, Nochioka K. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thrombo Vasc Biol 2013; 33: 1591-1600 DOI: 10.1161/ATVBAHA.112.300922..
• 54 Kjekshus J, Apetrei E, Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261
• 55 Kudo S, Satoh K, Nogi M. SmgGDS as a Crucial mediator of the inhibitory effects of statins on cardiac hypertrophy and fibrosis: novel mechanism of the pleiotropic effects of statins. Hypertension 2016; 67: 878-889 DOI: 10.1161/HYPERTENSIONAHA.115.07089.
• 56 Antoniades C, Demosthenous M, Reilly S. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 2012; 59: 60-70 DOI: 10.1016/j.jacc.2011.08.062..
• 57 Del DP, Miyamoto S, Brown JH. RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 2007; 282: 8069-8078 DOI: 10.1074/jbc. M604298200.
• 58 Okamoto R, Li Y, Noma K. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB Journal 2013; 27: 1439-1449 DOI: 10.1096/fj.12-217018.
• 59 Calò LA, Vertolli U, Pagnin E. et al. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications. Life Sci 2016; 148: 80-85 DOI: 10.1016/j.lfs.2016.02.019.
• 60 Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-648 DOI: 10.1016/j.jacc.2003.07.049.
• 61 Tavazzi L, Maggioni AP, Marchioli R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSIHF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239 DOI: 10.1016/S0140-6736(08)61240-4.
• 62 Pignatelli P, Carnevale R, Pastori D. et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circ 2012; 126: 92-103 DOI: 10.1161/CIRCULATIONAHA.112.095554.
• 63 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861 DOI: 10.1056/NEJMoa0900241.
• 64 Dichtl W, Dulak J, Frick M. et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63 DOI: 10.1161/01.atv.0000043456.48735.20.
• 65 Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,  - 2,  - 3, and  - 9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 22003 23: 769-775 DOI: 10.1161/01.ATV.0000068646.76823.AE.
• 66 Kagami S, Owada T, Kanari H. et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+regulatory T cells. Int Immunol 2009; 21: 679-689 DOI: 10.1093/intimm/dxp037.
• 67 Sato K, Nuki T, Gomita K. et al. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expres sion on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010; 213: 33-39 DOI: 10.1016/j.atherosclerosis.2010.03.034.
• 68 Wei H, Fang L, Song J. et al. Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. FEBS Letters 2005; 579: 1272-1278 DOI: 10.1016/j.febslet.2005.01.020.
• 69 Yusuf S, Bosch J, Dagenais G. et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374: 2021-2031 DOI: 10.1056/NEJMoa1600176.
• 70 de Lemos JA, Blazing MA, Wiviott SD. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316 DOI: 10.1001/jama.292.11.1307.
• 71 Kinlay S, Schwartz GG, Olsson AG. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circ 2003; 108: 1560-1566 DOI: 10.1161/01.CIR.0000091404.09558.AF.
• 72 Andrade J, Khairy P, Dobrev D. et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453-1468 DOI: 10.1161/CIRCRESAHA.114.303211.
• 73 Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111 DOI: 10.1016/j.cardiores.2004.01.018.
• 74 Yaghi S, Elkind MS. Lipids and Cerebrovascular Disease: Research and Practice. Stroke 2015; 46: 3322-3328 DOI: 10.1161/STROKEAHA.115.011164..
• 75 Maggioni AP, Fabbri G, Lucci D. et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-2336 DOI: 10.1093/eurheartj/ehp357.
• 76 Schwartz GG, Chaitman BR, Goldberger JJ. et al. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J 2011; 161: 993-999 DOI: 10.1016/j.ahj.2011.02.002.
• 77 Fang WT, Li HJ, Zhang H. et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012; 74: 744-756 DOI: 10.1111/j.1365-2125.2012.04258.x.
• 78 Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015; 116: 1887-1906 DOI: 10.1161/CIRCRESAHA.116.304521.
• 79 Redfors B, Ramunddal T, Angeras O. et al. Angiographic findings and survival in patients undergoing coronary angiography due to sudden cardiac arrest in western Sweden. Resuscitation 2015; 90: 13-20 DOI: 10.1016/j.resuscitation.2014.11.034.
• 80 Dekker LR, Bezzina CR, Henriques JP. et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circ 2006; 114: 1140-1145 DOI: 10.1161/CIRCULATIONAHA.105.606145.
• 81 Albert CM, Ma J, Rifai N. et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circ 2002; 105: 2595-2599 DOI: 10.1161/01.CIR.0000017493.03108.1C.
• 82 Chiu JH, Abdelhadi RH, Chung MK. et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverterdefibrillator. Am J Cardiol 2002; 95: 490-491 DOI: 10.1016/j.amjcard.2004.10.017.
• 83 Vyas AK, Guo H, Moss AJ. et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 769-773 DOI: 10.1016/j.jacc.2005.09.053.
• 84 Buber J, Goldenberg I, Moss AJ. et al. (2012). Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol 2012; 60: 749-755 DOI: 10.1016/j.jacc.2012.03.041.